Trials / Completed
CompletedNCT05084222
Use of Buventol Easyhaler and Bufomix Easyhaler in Methacoline Challenge Testing
Use of Buventol Easyhaler and Bufomix Easyhaler as Relievers in Methacholine Challenge Testing and Inspiratory Flow Profiles During Induced Bronchoconstriction in Adult Subjects
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 180 (actual)
- Sponsor
- Orion Corporation, Orion Pharma · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study compares Buventol® Easyhaler® and Bufomix® Easyhaler® to the current standard treatment during methacholine challenge test. The trial will also provide inspiratory flow profile data for Easyhaler inhaler. This trial is designed to provide a further evidence for the use of Easyhaler in diagnostic bronchial challenge tests and on the use of Easyhaler inhaler during obstructive event.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Buventol® Easyhaler® 200 µg/inhalation dmDPI | Two doses will be administered |
| DRUG | Bufomix® Easyhaler® 160/4.5 µg/inhalation dmDPI | Two doses will be administered |
| DRUG | Ventoline® Evohaler® 100 µg/inhalation pMDI | Four doses will be administered via Volumatic spacer |
Timeline
- Start date
- 2021-11-11
- Primary completion
- 2023-06-30
- Completion
- 2023-06-30
- First posted
- 2021-10-19
- Last updated
- 2023-09-05
Locations
2 sites across 1 country: Finland
Source: ClinicalTrials.gov record NCT05084222. Inclusion in this directory is not an endorsement.